1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
XBiotech Inc.

XBiotech Inc.

XBIT
XBiotech Inc.US flagNASDAQ Global Select
2.00
USD
-0.12
- -
60.98MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
1.43
0.61
0.13
- -
- -
- -
- -
Basic EPS, GAAP
-0.31
-0.68
-1.22
-1.63
-0.95
-0.59
17.17
-0.36
-0.58
-1.08
-0.81
-1.26
-1.49
-1.48
Free Cash Flow per Basic Share
-0.28
-0.41
-1.42
-1.85
-1.01
-0.47
-0.47
-2.23
2.19
-0.51
-0.63
-1.06
-1.32
-1.34
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
2.5
- -
- -
- -
- -
- -
Book Value per Share
0.32
1.86
3.19
1.81
1.7
1.15
18.2
11.9
8.85
7.9
7.19
5.98
4.6
4.21
Tangible Book Value per Share
0.32
1.86
3.19
1.81
1.7
1.15
18.2
11.9
8.85
7.9
7.19
5.98
4.6
4.21
Basic Weighted Avg Shares
32
32
31
32
35
36
39
31
30
30
30
30
30
30
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
44
18
4
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
-41.54
-136.36
-860.1
- -
- -
- -
- -
Depreciation Expense
1
1
1
1
1
2
2
2
3
3
2
2
2
1
Net Income, GAAP
-10
-22
-37
-53
-33
-21
669
-11
-17
-33
-25
-39
-46
-45
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
6.93
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-25.5
-94.67
-820.45
- -
- -
- -
- -
Working Capital
7
55
87
29
31
14
656
322
243
216
196
159
119
108
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
10
59
103
59
60
41
756
349
269
240
219
182
140
128
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
-6.87
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
167.78
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-112.81
-62.73
-46.25
-65.09
-55.61
-41.63
167.78
-2.03
-5.64
-12.91
-10.69
-19.21
-28.23
-29.94

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
30
30
Market Capitalization
73
72
70

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
127
117
111
Cash, Cash Equivalents & STI
126
115
110
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
3
3
Payables & Accruals
3
3
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
151.72%
-16.43%
-23%
Free Cash Flow
2.53%
-40.31%
24.61%
Net Income, GAAP
-320.36%
38.77%
18.19%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.33
-0.43
-0.16
- -
-1.26
2025
-0.36
-0.06
-0.2
- -
-1.49
2026
-0.18
-0.22
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sushma Shivaswamy
Full Time Employees
87
Sector
Healthcare
Industry
Biotechnology
Address
5217 Winnebago Lane Austin TX United States of America 78744
IPO Date
Apr 15, 2015
CIK
0001626878
Website
xbiotech.com
Similar Companies
Klotho Neurosciences, Inc. (KLTOW)
Carisma Therapeutics, Inc. (CARM)
Antengene Corporation Limited (6996.HK)
Addex Therapeutics Ltd (ADXN.SW)
Onesource Specialty Pharma Ltd. (ONESOURCE.NS)
Synlogic, Inc. (SYBX)
Business
XBiotech Inc. (Nasdaq:XBIT), a clinical-stage biopharmaceutical company founded in 2005 and headquartered in Austin, Texas, discovers, develops and commercializes True Human monoclonal antibodies derived from natural human immunity for treating inflammatory diseases, infectious diseases and oncology indications; its lead product candidate Natrunix, a True Human antibody targeting interleukin-1 alpha (IL-1α), is advancing in a Phase II portion of the TASKIN study combined with trifluridine/tipiracil for advanced colorectal cancer; the company is also developing therapies such as bermekimab for inflammatory conditions including cancer and an Unmetix cocktail for shingles. XBiotech operates a fully integrated research, development and manufacturing facility in Austin with a separate infectious disease laboratory; it previously maintained a German subsidiary, XBiotech Germany GmbH, which was dissolved in February 2023; the company targets unmet medical needs in areas such as rheumatology, cardiovascular disease, stroke, heart attack, arthritis and tissue breakdown mediated by IL-1α. In November 2024, XBiotech completed non-clinical data for its novel shingles therapy Unmetix and prepared an Investigational New Drug application submission; in October 2024, it reported ongoing enrollment in the Phase II TASKIN trial for Natrunix; in September 2024, the company successfully completed a U.S. FDA GLP inspection at its facilities.

Company News

Company News APIChatGPT

  • globenewswire.com

    XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer

  • defenseworld.net

    XBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50-Day Moving Average – What’s Next?

  • globenewswire.com

    XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis

  • defenseworld.net

    Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)

  • defenseworld.net

    Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)

  • defenseworld.net

    XBiotech (NASDAQ:XBIT) Share Price Crosses Above Fifty Day Moving Average – Should You Sell?

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

  • accessnewswire.com

    The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

  • accessnewswire.com

    XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm